Magnolia Capital Advisors LLC Has $638,000 Stake in DexCom, Inc. (NASDAQ:DXCM)

Magnolia Capital Advisors LLC grew its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,198 shares of the medical device company’s stock after buying an additional 210 shares during the quarter. Magnolia Capital Advisors LLC’s holdings in DexCom were worth $638,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in DXCM. Jennison Associates LLC lifted its holdings in shares of DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after buying an additional 6,544,102 shares during the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after buying an additional 876,739 shares during the last quarter. Two Sigma Advisers LP lifted its holdings in shares of DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock valued at $76,659,000 after buying an additional 739,000 shares during the last quarter. Intech Investment Management LLC lifted its holdings in DexCom by 2,083.0% in the 3rd quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock worth $25,967,000 after purchasing an additional 369,587 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in DexCom by 53.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock worth $66,352,000 after purchasing an additional 345,114 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,342 shares of company stock worth $3,628,069 over the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on DXCM shares. Royal Bank of Canada reduced their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Canaccord Genuity Group boosted their target price on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Leerink Partners reduced their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, Raymond James reduced their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.29.

DexCom Trading Down 0.9 %

NASDAQ:DXCM opened at $86.83 on Monday. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The business’s 50-day moving average price is $80.77 and its two-hundred day moving average price is $76.21. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $33.92 billion, a price-to-earnings ratio of 51.99, a PEG ratio of 2.23 and a beta of 1.14.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.